Polypharmacy in primary care: A population-based retrospective cohort study of electronic health records
Polypharmazie in der Primärversorgung: populationsbasierte retrospektive Kohortenstudie mit elektronischen Gesundheitsakten
PLOS ONE · 04.09.2024 · 19 (9) · e0308624
DOI: 10.1371/journal.pone.0308624 ↗Auf einen Blick
In 1,7 Millionen Erwachsenen war Polypharmazie häufig und mit Alter, Deprivation und Gebrechlichkeit assoziiert. Die jährlichen Medikamentenkosten waren bei Polypharmazie höher.
Fragestellung
Wie häufig ist Polypharmazie in der Primärversorgung und wie hängen Patient:innenmerkmale mit Prävalenz und Medikamentenkosten zusammen?
Methode
Retrospektive Kohortenstudie mit elektronischen Gesundheitsakten aus North West London; Polypharmazie als 5 oder mehr regelmäßige Medikamente; Analyse nach Demografie und Gebrechlichkeit.
Ergebnisse
Von 1,7 Millionen Erwachsenen hatten 167.665 (9,4 %) Polypharmazie. Assoziationen mit Alter, Deprivation, Gebrechlichkeit, Geschlecht und Ethnie wurden per logistischer Regression beschrieben. Jahreskosten: £370.89 vs. £45.31.
Schlussfolgerung der Autor:innen
Demografische Merkmale waren nach Adjustierung für Gebrechlichkeit mit Polypharmazie assoziiert. Weitere Forschung soll die Ursachen klären, um Ungleichheiten zu verringern und Kosten zu optimieren.
Kernaussagen
- Polypharmazie betraf 167.665 von 1,7 Millionen Erwachsenen
- Alter, Deprivation und Gebrechlichkeit waren damit assoziiert
- Jährliche Medikamentenkosten waren bei Polypharmazie 8,2-fach höher
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS ONE, online erschienen am 04.09.2024. Verfasst von Thomas Woodcock und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom. Hauptthemen laut MEDLINE: Polypharmacy, Electronic Health Records, Primary Health Care. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, National Institute for Health and Care Research (NIHR) Applied Research Collaboration Northwest London, NIHR North West London Patient Safety Research Collaboration.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Background
Polypharmacy, prescription of multiple medications to a patient, is a major challenge for health systems. There have been no peer-reviewed studies of polypharmacy prevalence and medication cost at a population level in England.
Aims
To determine prevalence and medication cost of polypharmacy, by patient characteristics. Design and setting: Retrospective cohort study of North West London electronic health records Method We quantified prevalence and direct cost of polypharmacy (five or more regular medications), stratified by demographics and frailty. We fitted a mixed-effects logistic regression for polypharmacy.
Results
Of 1.7 million adults, 167,665 (9.4%) were on polypharmacy. Age and socio-economic deprivation were associated with polypharmacy (OR 9.24 95% CI 8.99 to 9.50, age 65–74 compared with 18–44; OR 0.68 95% CI 0.65 to 0.71, least deprived compared with most). Polypharmacy prevalence increased with frailty (OR 1.53 95% CI 1.53 to 1.54 per frailty component, for White women). Men had higher odds of polypharmacy than women at average frailty (OR 1.26 95% CI 1.24 to 1.28) and with additional frailty components (OR 1.10 95% CI 1.09 to 1.10). Black people had lower odds of polypharmacy at average frailty (OR 0.82 95% CI 0.79 to 0.85, compared with White), but along with other ethnicities, saw greater odds increases with increasing frailty (OR 1.02 95% CI 1.01 to 1.03). Annual medication cost 8.2 times more for those on polypharmacy compared with not (£370.89 and £45.31).
Conclusion
Demographic characteristics are associated with polypharmacy, after adjusting for frailty. Further research should explore why, to reduce health inequities and optimise cost associated with polypharmacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom.
- Department of Primary Care and Public Health, NIHR ARC Northwest London, School of Public Health, Imperial College London, London, United Kingdom.
- Chelsea And Westminster Hospital NHS Foundation Trust, London, United Kingdom.
ORCID-Profile: Thomas Woodcock, Derryn Lovett
Förderung
- Wellcome Trust
- National Institute for Health and Care Research (NIHR) Applied Research Collaboration Northwest London
- NIHR North West London Patient Safety Research Collaboration
- Wellcome Trust Fellowship
Zitieren
APA
Woodcock, T., Lovett, D., Ihenetu, G., Novov, V., Beaney, T., Armani, K., Quilley, A., Majeed, A., & Aylin, P. (2024). Polypharmacy in primary care: A population-based retrospective cohort study of electronic health records. PLOS ONE, 19(9), e0308624. https://doi.org/10.1371/journal.pone.0308624
Vancouver
Woodcock T, Lovett D, Ihenetu G, Novov V, Beaney T, Armani K, et al. Polypharmacy in primary care: A population-based retrospective cohort study of electronic health records. PLOS ONE. 2024;19(9):e0308624. doi:10.1371/journal.pone.0308624
BibTeX
@article{Woodcock2024,
author = {Woodcock, Thomas and Lovett, Derryn and Ihenetu, Gloria and Novov, Vesselin and Beaney, Thomas and Armani, Keivan and Quilley, Angela and Majeed, Azeem and Aylin, Paul},
title = {Polypharmacy in primary care: A population-based retrospective cohort study of electronic health records},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {9},
pages = {e0308624},
doi = {10.1371/journal.pone.0308624}
}
EUVIMED